Central Nervous System Tumor, Head and Neck Neoplasms
Conditions
Brief summary
The participants are being asked to get this PET scan because the participants have or may have cancer in the central nervous system (head, neck, or spine), and the investigator and the patient's physician thinks that this scan may provide useful information for the participant's treatment. Primary Objective To provide expanded access to L-\[11C\]methionine as a positron-emitting tracer in children and young adults for the positron emission tomography (PET) imaging of neoplasms of the central nervous system (CNS) and head and neck to guide therapeutic management of disease.
Detailed description
Participants receive an intravenous injection of a small (tracer) dose of L-\[11C\]methionine. Approximately 10 minutes later, patients undergo PET scanning to evaluate localization of the tracer.
Interventions
DRUGL-(11C) methionine
Injected intravenously with 20 mCi/1.7 sq m body surface area of L-\[methyl-11C\]methionine (maximum prescribed dose: 20 mCi).
Sponsors
St. Jude Children's Research Hospital
Eligibility
Sex/Gender
ALL
Inclusion criteria
* All participants under the care of a SJCRH physician with known or suspected neoplastic disease of the CNS or head and neck are eligible for participation. * No limit on age. * Patients of all genders and all ethnic groups under the care of a SJCRH physician. * Female participants of child-bearing age must not be lactating due to theoretical potential harm to the infant from exposure to radiation. * Informed consent signed by participant, parent, or guardian according to the guidelines of the Institutional Review Board.
Exclusion criteria
* More than six L-\[11C\]methionine PET scans within the previous 12 months. * Inability or willingness of patient, parent, or guardian to consent.
Countries
United States
Contacts
CONTACTBarry L. Shulkin, MD, MBA
PRINCIPAL_INVESTIGATORBarry L. Shulkin, MD, MBA
St. Jude Children's Research Hospital
Outcome results
None listed